Analysts at Canaccord Genuity initiated coverage on shares of Actinium Pharmaceuticals ATNM with a Buy rating.
The target price for Actinium Pharmaceuticals is set to $16.
Actinium Pharmaceuticals shares have surged 104.12% over the past 52 weeks, while the S&P 500 index has jumped 16.40% in the same period.
Actinium Pharmaceuticals' shares declined 4.28% to close at $6.94 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in